Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study
Marie Hauguel-Moreau,Paul Guedeney,Claire Dauphin,Vincent Auffret,Eloi Marijon,Philippe Aldebert,Jean-Michel Clerc,Farzin Beygui,Meyer Elbaz,Wissam Abi Khalil,Antoine Da Costa,Jean-Christophe Macia,Simon Elhadad,Guillaume Cayla,Delphine Brugier,Johanne Silvain,Nadjib Hammoudi,Guillaume Duthoit,Eric Vicaut,Gilles Montalescot,Gilles Montalescot,Marie Hauguel-Moreau,Guillaume Duthoit,Eric Vicaut,Mikael Laredo,Thomas Rolland,Yassine Temmar,Nicolas Lellouche,Gilles Chatellier,Stéphane Edhery,Gilles Montalescot,Claire Dauphin,Vincent Auffret,Eloi Marijon,Farzin Beygui,Philippe Aldebert,Jean-Michel Clerc,Meyer Elbaz,Jean-Christophe Macia,Antoine Da Costa,Wissam Abi Khalil,Simon Elhadad,Guillaume Cayla,Xavier Iriart,
DOI: https://doi.org/10.1093/ehjcvp/pvad100
2024-01-12
European Heart Journal - Cardiovascular Pharmacotherapy
Abstract:Abstract Introduction Atrial arrhythmia is the most common complication of patent foramen ovale (PFO) closure. The real incidence of post-PFO closure atrial arrhytmia and whether this complication can be prevented is unknown. Methods/Design The Assessment of Flecainide to Lower the PFO closure risk of Atrial fibrillation or Tachycardia (AFLOAT) trial is a prospective, national, multicentre, randomized, open-label, superiority trial with a blind evaluation of all the endpoints (PROBE design). A total of 186 patients are randomized in a 1:1:1 ratio immediately after PFO closure to receive Flecainide (150 mg per day in a single sustained-release (SR) dose) for 6 months (Group 1), Flecainide (150 mg per day in a single SR dose) for 3 months (Group 2), or no additional treatment (standard of care) for 6 months (Group 3). The primary endpoint is the percentage of patients with at least one episode of symptomatic or asymptomatic atrial arrhythmia episode (≥30 s) recorded within 3 months after PFO closure on long-term monitoring with an insertable cardiac monitor. Whether 3 months of treatment is sufficient compared to 6 months will be analysed as a secondary objective of the study. Conclusion AFLOAT is the first trial to test the hypothesis that a short treatment with oral Flecainide can prevent the new-onset of atrial arrhythmia after PFO closure. Clinical trial registration NCT05213104 (clinicaltrials.gov).
pharmacology & pharmacy,cardiac & cardiovascular systems